Stocks Health care NBIX
NASDAQ · Health careNeurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc brought in $3.7B of revenue over the twelve months to September 30, 2026, up 38.0% from a year earlier. Net income was $702.5M, a net margin of 19.0%. Operating cash flow minus capital spending left $748.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $641.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Neurocrine Biosciences Inc
- Net worth
- Neurocrine Biosciences Inc has a market value (market cap) of $17.2B at the latest share price, and shareholders' equity of $3.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.9B (+21.4% year on year), with net income of $478.6M. Over the 12 months to September 30, 2026: revenue $3.7B, net income $702.5M.
- Cash flow
- In fiscal 2025 operations brought in $782.7M of cash; after $34M of capital spending, free cash flow was $748.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Neurocrine Biosciences Inc's next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Neurocrine Biosciences Inc does
Neurocrine Biosciences Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NBIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.9B | $478.6M | $4.67 | $748.7M |
| 2024 | $2.4B | $341.3M | $3.29 | $557.2M |
| 2023 | $1.9B | $249.7M | $2.47 | $361.6M |
| 2022 | $1.5B | $154.5M | $1.56 | $322.9M |
| 2021 | $1.1B | $89.6M | $0.92 | $233.1M |
| 2020 | $1B | $407.3M | $4.16 | $217.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NBIX ranks in Health care
Latest SEC filings
What Neurocrine Biosciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 41% to $1.1B versus the same quarter last year; diluted EPS $1.96 versus $2.04.
- November 2, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- September 28, 2026Executive or director change8-KNeurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer to succeed Sanjay Keswani, M.D.
- July 31, 2026
- July 31, 2026Exhibits 8-K/A
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 39% to $959M versus the same quarter last year; diluted EPS $1.39 versus $1.06.
- July 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- May 28, 2026
What is NBIX worth? A DCF from its reported cash flow
Insider trades
What the people running Neurocrine Biosciences Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Morrow George JDirector | Exercised options | 7,200 | $386.2K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 100 | $15.8K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 100 | $16.2K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 600 | $98.2K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 1,226 | $202K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 908 | $150.5K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 1,466 | $244.5K |
| November 3, 2026 | Morrow George JDirector | Soldpre-planned (10b5-1) | 1,500 | $251.6K |
Who owns NBIX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dodge & Cox13G, passive | 5.6% | May 14, 2025 |
| Vanguard Capital Management13G, passive | 5.23% | April 30, 2026 |
| Vanguard Portfolio Management13G, passive | 5% | October 30, 2026 |
Largest institutional holders
Insiders
19 insiders reported holding 1,163,656 shares in total, about $196.8M at the last price.
| Holder | Shares |
|---|---|
| Gorman Kevin CharlesDirector | 517,797 |
| Gano KyleChief Executive Officer, Director | 155,010 |
| Lyons Gary ADirector | 122,141 |
| Benevich EricChief Commercial Officer | 67,297 |
| Lippoldt DarinChief Legal Officer | 56,793 |
| Rastetter William HDirector | 43,678 |
| Abernethy MattChief Financial Officer | 42,808 |
| Pops Richard FDirector | 37,798 |
| Cooke JulieChief Human Resources Officer | 24,025 |
| Onyia JudeChief Scientific Officer | 22,647 |
Questions about NBIX
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is a company in the Health care sector, listed on NASDAQ as NBIX. Its shares trade on NASDAQ under the ticker NBIX.
What is Neurocrine Biosciences Inc's net worth?
Neurocrine Biosciences Inc has a market value (market cap) of $17.2B at the latest share price, and shareholders' equity of $3.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Neurocrine Biosciences Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $702.5M on revenue of $3.7B, a net margin of 19.0%.
How much revenue does Neurocrine Biosciences Inc make?
Over the twelve months to September 30, 2026 Neurocrine Biosciences Inc reported revenue of $3.7B. That is 38.0% more than a year earlier.
When did Neurocrine Biosciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Neurocrine Biosciences Inc's next earnings report?
Neurocrine Biosciences Inc's next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NBIX with
Follow NBIX
Get an email when Neurocrine Biosciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Neurocrine Biosciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.